Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors

Science Signaling

Volumn 9, Issue 450, 2016, Pages

  Zhang, Guolin ^a   Scarborough, Hannah ^b   Kim, Jihye ^c   Rozhok, Andrii I ^b   Chen, Yian Ann ^a   Zhang, Xiaohui ^a   Song, Lanxi ^a   Bai, Yun ^a   Fang, Bin ^a   Liu, Richard Z ^a   Koomen, John ^a   Tan, Aik Choon ^c   Degregori, James ^b   Haura, Eric B ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; FIBROBLAST GROWTH FACTOR RECEPTOR SUBSTRATE 2; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN CC2D1A; SCAFFOLD PROTEIN; SHORT HAIRPIN RNA; TYROSINE; UNCLASSIFIED DRUG; CARBAZOLE DERIVATIVE; CC2D1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; EML4 PROTEIN, HUMAN; FRS2 PROTEIN, HUMAN; MEMBRANE PROTEIN; PIPERIDINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SERINE PROTEINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

AFFINITY CHROMATOGRAPHY; ARTICLE; CELL FUSION; CONTROLLED STUDY; DRUG RESISTANCE; DRUG TARGETING; EMBRYO; FUSION GENE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MASS SPECTROMETRY; PHOSPHOPROTEOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; RNAI THERAPEUTICS; ANTAGONISTS AND INHIBITORS; GENETICS; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARBAZOLES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; PIPERIDINES; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RNA INTERFERENCE; SERINE ENDOPEPTIDASES;

EID: 84991829690     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aaf5011     Document Type: Article

References (76)

1. S. V. Sharma, P. Gajowniczek, I. P. Way, D. Y. Lee, J. Jiang, Y. Yuza, M. Classon, D. A. Haber, J. Settleman, A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10, 425-435 (2006).
2. P. T. Tran, P. K. Bendapudi, H. J. Lin, P. Choi, S. Koh, J. Chen, G. Horng, N. P. Hughes, L. H. Schwartz, V. A. Miller, T. Kawashima, T. Kitamura, D. Paik, D. W. Felsher, Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci. Transl. Med. 3, 103ra99 (2011).
3. M. Ramirez, S. Rajaram, R. J. Steininger, D. Osipchuk, M. A. Roth, L. S. Morinishi, L. Evans, W. Ji, C.-H. Hsu, K. Thurley, S. Wei, A. Zhou, P. R. Koduru, B. A. Posner, L. F. Wu, S. J. Altschuler, Diverse drug-resistance mechanisms can emerge from drug-Tolerant cancer persister cells. Nat. Commun. 7, 10690 (2016).
4. A. N. Hata, M. J. Niederst, H. L. Archibald, M. Gomez-Caraballo, F. M. Siddiqui, H. E. Mulvey, Y. E. Maruvka, F. Ji, H.-e. C. Bhang, V. K. Radhakrishna, G. Siravegna, H. Hu, S. Raoof, E. Lockerman, A. Kalsy, D. Lee, C. L. Keating, D. A. Ruddy, L. J. Damon, A. S. Crystal, C. Costa, Z. Piotrowska, A. Bardelli, A. J. Iafrate, R. I. Sadreyev, F. Stegmeier, G. Getz, L. V. Sequist, A. C. Faber, J. A. Engelman, Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262-269 (2016).
5. T. G. Bivona, R. C. Doebele, A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat. Med. 22, 472-478 (2016).
6. I. Astsaturov, V. Ratushny, A. Sukhanova, M. B. Einarson, T. Bagnyukova, Y. Zhou, K. Devarajan, J. S. Silverman, N. Tikhmyanova, N. Skobeleva, A. Pecherskaya, R. E. Nasto, C. Sharma, S. A. Jablonski, I. G. Serebriiskii, L. M. Weiner, E. A. Golemis, Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci. Signal. 3, ra67 (2010).
7. J. Li, K. Bennett, A. Stukalov, B. Fang, G. Zhang, T. Yoshida, I. Okamoto, J.-Y. Kim, L. Song, Y. Bai, X. Qian, B. Rawal, M. Schell, F. Grebien, G. Winter, U. Rix, S. Eschrich, J. Colinge, J. Koomen, G. Superti-Furga, E. B Haura, Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Mol. Syst. Biol. 9, 705 (2013).
8. J. B. Fitzgerald, B. Schoeberl, U. B. Nielsen, P. K. Sorger, Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2, 458-466 (2006).
9. M. Soda, Y. L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, S.-i. Fujiwara, H. Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, H. Mano, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007).
10. E. L. Kwak, Y.-J. Bang, D. R. Camidge, A. T. Shaw, B. Solomon, R. G. Maki, S.-H. I. Ou, B. J. Dezube, P. A. Jänne, D. B. Costa, M. Varella-Garcia, W.-H. Kim, T. J. Lynch, P. Fidias, H. Stubbs, J. A. Engelman, L. V. Sequist, W. Tan, L. Gandhi, M. Mino-Kenudson, G. C. Wei, S. M. Shreeve, M. J. Ratain, J. Settleman, J. G. Christensen, D. A. Haber, K. Wilner, R. Salgia, G. I. Shapiro, J. W. Clark, A. J. Iafrate, Anaplastic lymphoma kinase inhibition in non-smallcell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
11. A. T. Shaw, B. Y. Yeap, M. Mino-Kenudson, S. R. Digumarthy, D. B. Costa, R. S. Heist, B. Solomon, H, S. Admane, U. McDermott, J. Settleman, S. Kobayashi, E. J. Mark, S. J. Rodig, L. R. Chirieac, E. L. Kwak, T. J. Lynch, A. J. Iafrate, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, 4247-4253 (2009).
12. Y. L. Choi, M. Soda, Y. Yamashita, T. Ueno, J. Takashima, T. Nakajima, Y. Yatabe, K. Takeuchi, T. Hamada, H. Haruta, Y. Ishikawa, H. Kimura, T. Mitsudomi, Y. Tanio, H. Mano; ALK Lung Cancer Study Group, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734-1739 (2010).
13. F. H. Wilson, C. M. Johannessen, F. Piccioni, P. Tamayo, J. W. Kim, E. M. Van Allen, S. M. Corsello, M. Capelletti, A. Calles, M. Butaney, T. Sharifnia, S. B. Gabriel, J. P. Mesirov, W. C. Hahn, J. A. Engelman, M. Meyerson, D. E. Root, P. A. Jänne, L. A. Garraway, A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell 27, 397-408 (2015).
14. H. Sakamoto, T. Tsukaguchi, S. Hiroshima, T. Kodama, T. Kobayashi, T. A. Fukami, N. Oikawa, T. Tsukuda, N. Ishii, Y. Aoki, CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19, 679-690 (2011).
15. A. T. Shaw, D.-W. Kim, R. Mehra, D. S.W. Tan, E. Felip, L. Q. M. Chow, D. R. Camidge, J. Vansteenkiste, S. Sharma, T. De Pas, G. J. Riely, B. J. Solomon, J. Wolf, M. Thomas, M. Schuler, G. Liu, A. Santoro, Y. Y. Lau, M. Goldwasser, A. L. Boral, J. A. Engelman, Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370, 1189-1197 (2014).
16. C. M. Lovly, N. T. McDonald, H. Chen, S. Ortiz-Cuaran, L. C. Heukamp, Y. Yan, A. Florin, L. Ozretic, D. Lim, L. Wang, Z. Chen, X. Chen, P. Lu, P. K Paik, R. Shen, H. Jin, R. Buettner, S. Ansén, S. Perner, M. Brockmann, M. Bos, J. Wolf, M. Gardizi, G. M. Wright, B. Solomon, P. A. Russell, T.-M. Rogers, Y. Suehara, M. Red-Brewer, R. Tieu, E. de StanChina, Q. Wang, Z. Zhao, D. H Johnson, L. Horn, K.-K. Wong, R. K Thomas, M. Ladanyi, W. Pao, Rationale for co-Targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat. Med. 20, 1027-1034 (2014).
17. M. Kimura, H. Endo, T. Inoue, K. Nishino, J. Uchida, T. Kumagai, Y. Kukita, K. Kato, F. Imamura, M. Inoue, Analysis of ERBB ligand-induced resistance mechanism to crizotinib by primary culture of lung adenocarcinoma with EML4-ALK fusion gene. J. Thorac. Oncol. 10, 527-530 (2015).
18. R. Katayama, A. T. Shaw, T. M. Khan, M. Mino-Kenudson, B. J. Solomon, B. Halmos, N. A. Jessop, J. C. Wain, A. Tien, Y. C. Benes, L. Drew, J. C. Saeh, K. Crosby, L. V. Sequist, A. J. Iafrate, J. A. Engelman, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4, 120ra17 (2012).
19. J. Sang, J. Acquaviva, J. C. Friedland, D. L. Smith, M. Sequeira, C. Zhang, Q. Jiang, L. Xue, C. M. Lovly, J.-P. Jimenez, A. T. Shaw, R. C. Doebele, S. He, R. C. Bates, D. R. Camidge, S. W. Morris, I. El-Hariry, D. A. Proia, Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 3, 430-433 (2013).
20. F. Wu, P. Wang, L. C. Young, R. Lai, L. Li, Proteome-wide identification of novel binding partners to the oncogenic fusion gene protein, NPM-ALK, using tandem affinity purification and mass spectrometry. Am. J. Pathol. 174, 361-370 (2009).
21. D. K. Crockett, Z. Lin, K. S. Elenitoba-Johnson, M. S. Lim, Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene 23, 2617-2629 (2004).
22. L. Riera, E. Lasorsa, C. Ambrogio, N. Surrenti, C. Voena, R. Chiarle, Involvement of Grb2 adaptor protein in nucleophosmin-Anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. J. Biol. Chem. 285, 26441-26450 (2010).
23. R.-Y. Bai, T. Ouyang, C. Miething, S. W. Morris, C. Peschel, J. Duyster, Nucleophosminanaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96, 4319-4327 (2000).
24. G. Hrustanovic, V. Olivas, E. Pazarentzos, A. Tulpule, S. Asthana, C. M. Blakely, R. A. Okimoto, L. Lin, D. S. Neel, A. Sabnis, J. Flanagan, E. Chan, M. Varella-Garcia, D. L. Aisner, A. Vaishnavi, S.-H. I. Ou, E. A. Collisson, E. Ichihara, P. C. Mack, C. M. Lovly, N. Karachaliou, R. Rosell, J. W. Riess, R. C. Doebele, T. G. Bivona, RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat. Med. 21, 1038-1047 (2015).
25. J. P. Koivunen, C. Mermel, K. Zejnullahu, C. Murphy, E. Lifshits, A. J. Holmes, H. G. Choi, J. Kim, D. Chiang, R. Thomas, J. Lee, W. G. Richards, D. J. Sugarbaker, C. Ducko, N. Lindeman, J. P. Marcoux, J. A. Engelman, N. S. Gray, C. Lee, M. Meyerson, P. A. Jänne, EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 14, 4275-4283 (2008).
26. A. C.-Y. Lai, C.-F. Tsai, C.-C. Hsu, Y.-N. Sun, Y.-J. Chen, Complementary Fe3+-And Ti4+-immobilized metal ion affinity chromatography for purification of acidic and basic phosphopeptides. Rapid Commun. Mass Spectrum. 26, 2186-2194 (2012).
27. A. Chatr-Aryamontri, B.-J. Breitkreutz, R. Oughtred, L. Boucher, S. Heinicke, D. Chen, C. Stark, A. Breitkreutz, N. Kolas, L. O'Donnell, T. Reguly, J. Nixon, L. Ramage, A. Winter, A. Sellam, C. Chang, J. Hirschman, C. Theesfeld, J. Rust, M. S. Livstone, K. Dolinski, M. Tyers, The BioGRID interaction database: 2015 update. Nucleic Acids Res. 43, D470-D478 (2015).
28. P. V. Hornbeck, J. M. Kornhauser, S. Tkachev, B. Zhang, E. Skrzypek, B. Murray, V. Latham, M. Sullivan, PhosphoSitePlus: A comprehensive resource for investigating the structure and function of experimentally determined post-Translational modifications in man and mouse. Nucleic Acids Res. 40, D261-D270 (2012).
29. Y. Zheng, W. Yang, D. Hawke, D. X. Liu, Z. Lu, Ras-induced and extracellular signalregulated kinase 1 and 2 phosphorylation-dependent isomerization of protein tyrosine phosphatase (PTP)-PEST by PIN1 promotes FAK dephosphorylation by PTP-PEST. Mol. Cell. Biol. 31, 4258-4269 (2011).
30. T. Sun, N. Aceto, K. L. Meerbrey, J. D. Kessler, C. Zhou, I. Migliaccio, D. X. Nguyen, N. N. Pavlova, M. Botero, J. Huang, R. J. Bernardi, E. Schmitt, G. Hu, M. Z. Li, N. Dephoure, S. P. Gygi, M. Rao, C. J. Creighton, S. G. Hilsenbeck, C. A. Shaw, D. Muzny, R. A. Gibbs, D. A. Wheeler, C. K. Osborne, R. Schiff, M. Bentires-Alj, S. J. Elledge, T. F. Westbrook, Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell 144, 703-718 (2011).
31. A. J. Barr, E. Ugochukwu, W. H. Lee, O. N. F. King, P. Filippakopoulos, I. Alfano, P. Savitsky, N. A. Burgess-Brown, S. Müller, S. Knapp, Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 136, 352-363 (2009).
32. A. Koch, A. Mancini, O. El Bounkari, T. Tamura, The SH2-domian-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading. Oncogene 24, 3436-3447 (2005).
33. X. Pesesse, V. Dewaste, F. De Smedt, M. Laffargue, S. Giuriato, C. Moreau, B. Payrastre, C. Erneux, The Src homology 2 domain containing inositol 5-phosphatase SHIP2 is recruited to the epidermal growth factor (EGF) receptor and dephosphorylates phosphatidylinositol 3,4,5-Trisphosphate in EGF-stimulated COS-7 cells. J. Biol. Chem. 276, 28348-28355 (2001).
34. K. Backers, D. Blero, N. Paternotte, J. Zhang, C. Erneux, The termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases. Adv. Enzyme Regul. 43, 15-28 (2003).
35. T. Yoshida, G. Zhang, M. A. Smith, A. S. Lopez, Y. Bai, J. Li, B. Fang, J. Koomen, B. Rawal, K. J. Fisher, A. Y. Chen, M. Kitano, Y. Morita, H. Yamaguchi, K. Shibata, T. Okabe, I. Okamoto, K. Nakagawa, E. B. Haura, Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Clin. Cancer Res. 20, 4059-4074 (2014).
36. J.-F. Honorat, A. Ragab, L. Lamant, G. Delsol, J. Ragab-Thomas, SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling. Blood 107, 4130-4138 (2006).
37. D. Polgar, C. Leisser, S. Maier, S. Strasser, B. Rüger, M. Dettke, M. Khorchide, I. Simonitsch, C. Cerni, G. Krupitza, Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K. Mutat. Res. 570, 9-15 (2005).
38. K. Sattu, F. Hochgräfe, J. Wu, G. Umapathy, C. Schönherr, K. Ruuth, D. Chand, B. Witek, J. Fuchs, P.-K. Li, F. Hugosson, R. J. Daly, R. H. Palmer, B. Hallberg, Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells. FEBS J. 280, 5269-5282 (2013).
39. C. Ambrogio, C. Voena, A. D. Manazza, R. Piva, L. Riera, L. Barberis, C. Costa, G. Tarone, P. Defilippi, E. Hirsch, E. Boeri Erba, S. Mohammed, O. N. Jensen, G. Palestro, G. Inghirami, R. Chiarle, p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood 106, 3907-3916 (2005).
40. J. Degoutin, M. Vigny, J. Y. Gouzi, ALK activation induces Shc and FRS2 recruitment: Signaling and phenotypic outcomes in PC12 cells differentiation. FEBS Lett. 581, 727-734 (2007).
41. F. E. Boccalatte, C. Voena, C. Riganti, A. Bosia, L. D'Amico, L. Riera, M. Cheng, B. Ruggeri, O. N. Jensen, V. L. Goss, K. Lee, J. Nardone, J. Rush, R. D. Polakiewicz, M. J. Comb, R. Chiarle, G. Inghirami, The enzymatic activity of 5-Aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: New insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood 113, 2776-2790 (2009).
42. P. V. Hornbeck, B. Zhang, J. M. Kornhauser, V. Latham, E. Skrzypek, PhosphoSitePlus, 2014: Mutations, PTMs and recalibrations. Nucl. Acids Res. 43, D512-D520 (2015).
43. Z. Shaozhang, L. Xiaomei, Z. Aiping, H. Jianbo, S. Xiangqun, Y. Qitao, Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations. Genes Chromosomes Cancer 51, 925-932 (2012).
44. M. Eto, A. Karginov, D. L. Brautigan, A novel phosphoprotein inhibitor of protein type-1 phosphatase holoenzymes. Biochemistry 38, 16952-16957 (1999).
45. Y. Izumi, M. Hirata, H. Hasuwa, R. Iwamoto, T. Umata, K. Miyado, Y. Tamai, T. Kurisaki, A. Sehara-Fujisawa, S. Ohno, E. Mekada, A metalloprotease-disintegrin, MDC9/meltring/ADAM9 and PKCd are involved in TPA-induced ectodomain shedding of membraneanchored heparin-binding EGF-like growth factor. EMBO J. 17, 7260-7272 (1998).
46. Y. A. Kim, S. L. Park, M.-Y. Kim, S. H. Lee, E. J. Baik, C.-H. Moon, Y.-S. Jung, Role of PKCbII and PKCd in blood-brain barrier permeability during aglycemic hypoxia. Neurosci. Lett. 468, 254-258 (2010).
47. H.-L. Hsieh, W.-H. Tung, C.-Y. Wu, H.-H. Wang, C.-C. Lin, T.-S. Wang, C.-M. Yang, Thrombin induces EGF receptor expression and cell proliferation via a PKC(d)/c-Src-dependent pathway in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 29, 1594-1601 (2009).
48. T. Garofalo, M. Sorice, R. Misasi, B. Cinque, M. Giammatteo, G. M. Pontieri, M. Grazia Cifone, A. Pavan, A novel mechanism of CD4 down-modulation induced by monosialoganglioside GM3. Involvement of serine phosphorylation and protein kinase c d translocation. J. Biol. Chem. 273, 35153-35160 (1998).
49. Y. He, A. Wortmann, L. J. Burke, J. C. Reid, M. N. Adams, I. Abdul-Jabbar, J. P. Quigley, R. Leduc, D. Kirchhofer, J. D. Hooper, Proteolysis-induced N-Terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-Terminal domain and recruitment of Src and PKCd. J. Biol. Chem. 285, 26162-26173 (2010).
50. S.-H. Cho, H.-J. You, C.-H. Woo, Y.-J. Yoo, J.-H. Kim, Rac and protein kinase C-d regulate ERKs and cytosolic phospholipase A2 in FceRI signaling to cysteinyl leukotriene synthesis in mast cells. J. Immunol. 173, 624-631 (2004).
51. P. Csermely, T. Korcsmáros, H. J. M. Kiss, G. London, R. Nussinov, Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review. Pharmacol. Ther. 138, 333-408 (2013).
52. Z. Chen, T. Sasaki, X. Tan, J. Carretero, T. Shimamura, D. Li, C. Xu, Y. Wang, G. O. Adelmant, M. Capelletti, H. J. Lee, S. J. Rodig, C. Borgman, S.-i. Park, H. R. Kim, R. Padera, J. A. Marto, N. S. Gray, A. L. Kung, G. I. Shapiro, P. A. Jänne, K.-K. Wong, Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 70, 9827-9836 (2010).
53. A. Miyanaga, K. Shimizu, R. Noro, M. Seike, K. Kitamura, S. Kosaihira, Y. Minegishi, T. Shukuya, A. Yoshimura, M. Kawamoto, S. Tsuchiya, K. Hagiwara, M. Soda, K. Takeuchi, N. Yamamoto, H. Mano, Y. Ishikawa, A. Gemma, Activity of EGFR-Tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation. BMC Cancer 13, 262 (2013).
54. J. Tanizaki, I. Okamoto, T. Okabe, K. Sakai, K. Tanaka, H. Hayashi, H. Kaneda, K. Takezawa, K. Kuwata, H. Yamaguchi, E. Hatashita, K. Nishio, K. Nakagawa, Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin. Cancer Res. 18, 6219-6226 (2012).
55. A. Tanimoto, T. Yamada, S. Nanjo, S. Takeuchi, H. Ebi, K. Kita, K. Matsumoto, S. Yano, Receptor ligand-Triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Oncotarget 5, 4920-4928 (2014).
56. M. Taipale, I. Krykbaeva, M. Koeva, C. Kayatekin, K. D. Westover, G. I. Karras, S. Lindquist, Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell 150, 987-1001 (2012).
57. T. B. Schreiber, N. Mäusbacher, G. Kéri, J. Cox, H. Daub, An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol. Cell. Proteomics 9, 1047-1062 (2010).
58. J. Blouin, P. Roby, M. Arcand, L. Beaudet, F. Lipari, Catalytic specificity of human protein tyrosine kinases revealed by peptide substrate profiling. Curr. Chem. Genomics 5, 115-121 (2011).
59. T. Yamada, S. Takeuchi, N. Fujita, A. Nakamura, W. Wang, Q. Li, M. Oda, T. Mitsudomi, Y. Yatabe, Y. Sekido, J. Yoshida, M. Higashiyama, M. Noguchi, H. Uehara, Y. Nishioka, S. Sone, S. Yano, Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-Activating and gatekeeper mutations. Oncogene 32, 4427-4435 (2013).
60. T. Yamada, J. M. Amann, K. Fukuda, S. Takeuchi, N. Fujita, H. Uehara, S. Iwakiri, K. Itoi, K. Shilo, S. Yano, D. P. Carbone, Akt kinase-interacting protein 1 signals through CREB to drive diffuse malignant mesothelioma. Cancer Res. 75, 4188-4197 (2015).
61. A. S. Crystal, A. T. Shaw, L. V. Sequist, L. Friboulet, M. J. Niederst, E. L. Lockerman, R. L. Frias, J. F. Gainor, A. Amzallag, P. Greninger, D. Lee, A. Kalsy, M. Gomez-Caraballo, L. Elamine, E. Howe, W. Hur, E. Lifshits, H. E. Robinson, R. Katayama, A. C. Faber, M. M. Awad, S. Ramaswamy, M. Mino-Kenudson, A. J. Iafrate, C. H. Benes, J. A. Engelman, Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480-1486 (2014).
62. G. E. Winter, D. L. Buckley, J. Paulk, J. M. Roberts, A. Souza, S. Dhe-Paganon, J. E. Bradner, Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376-1381 (2015).
63. L. Basel-Vanagaite, R. Attia, M. Yahav, R. J. Ferland, L. Anteki, C. A. Walsh, T. Olender, R. Straussberg, N. Magal, E. Taub, V. Drasinover, A. Alkelai, D. Bercovich, G. Rechavi, A. J. Simon, M. Shohat, The CC2D1A, a member of a new gene family with C2 domains, is involved in autosomal recessive non-syndromic mental retardation. J. Med. Genet. 43, 203-210 (2006).
64. J. Reimand, T. Arak, J. Vilo, g: Profiler-A web server for functional interpretation of gene lists (2011 update). Nucleic Acids. Res. 39, W307-W315 (2011).
65. B. Aranda, H. Blankenburg, S. Kerrien, F. S. L. Brinkman, A. Ceol, E. Chautard, J. M. Dana, J. De Las Rivas, M. Dumousseau, E. Galeota, A. Gaulton, J. Goll, R. E. W. Hancock, R. Isserlin, R. C. Jimenez, J. Kerssemakers, J. Khadake, D. J. Lynn, M. Michaut, G. O'Kelly, K. Ono, S. Orchard, C. Prieto, S. Razick, O. Rigina, L. Salwinski, M. Simonovic, S. Velankar, A. Winter, G. Wu, G. D. Bader, G. Cesareni, I. M. Donaldson, D. Eisenberg, G. J. Kleywegt, J. Overington, S. Ricard-Blum, M. Tyers, M. Albrecht, H. Hermjakob, PSICQUIC and PSISCORE: Accessing and scoring molecular interactions. Nat. Methods 8, 528-529 (2011).
66. C. Y. Yang, C.-H. Chang, Y.-L. Yu, T.-C. E. Lin, S.-A. Lee, C.-C. Yen, J.-M. Yang, J.-M. Lai, Y.-R. Hong, T.-L. Tseng, K.-M. Chao, C.-Y. F. Huang, PhosphoPOINT: A comprehensive human kinase interactome and phospho-protein database. Bioinformatics 24, i14-i20 (2008).
67. L. Spinelli, P. Gambette, C. E. Chapple, B. Robisson, A. Baudot, H. Garreta, L. Tichit, A. Guénoche, C. Brun, Clust&See: A Cytoscape plugin for the identification, visualization and manipulation of network clusters. Biosystems 113, 91-95 (2013).
68. Y. Assenov, F. Ramírez, S.-E. Schelhorn, T. Lengauer, M. Albrecht, Computing topological parameters of biological networks. Bioinformatics 24, 282-284 (2008).
69. M. Casás-Selves, J. Kim, Z. Zhang, B. A. Helfrich, D. Gao, C. C. Porter, H. A. Scarborough, P. A. Bunn, D. C. Chan, A. C. Tan, J. DeGregori, Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 72, 4154-4164 (2012).
70. J. Kim, A. C. Tan, BiNGS!SL-seq: A bioinformatics pipeline for the analysis and interpretation of deep sequencing genome-wide synthetic lethal screen. Methods Mol. Biol. 802, 389-398 (2012).
71. B. Langmead, C. Trapnell, M. Pop, S. L. Salzberg, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
72. M. D. Robinson, D. J. McCarthy, G. K. Smyth, edgeR: A bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2010).
73. M. C. Whitlock, Combining probability from independent tests: The weighted Z-method is superior to Fisher's approach. J. Evol. Biol. 18, 1368-1373 (2005).
74. R. Marcotte, K. R. Brown, F. Suarez, A. Sayad, K. Karamboulas, P. M. Krzyzanowski, F. Sircoulomb, M. Medrano, Y. Fedyshyn, J. L. Y. Koh, D. van Dyk, B. Fedyshyn, M. Luhova, G. C. Brito, F. J. Vizeacoumar, F. S. Vizeacoumar, A. Datti, D. Kasimer, A. Buzina, P. Mero, C. Misquitta, J. Normand, M. Haider, T. Ketela, J. L. Wrana, R. Rottapel, B. G. Neel, J. Moffat, Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov. 2, 172-189 (2012).
75. J. Kim, V. T. Vasu, R. Mishra, K. R. Singleton, M. Yoo, S. M. Leach, E. Farias-Hesson, R. J. Mason, J. Kang, P. Ramamoorthy, J. A. Kern, L. E. Heasley, J. H. Finigan, A. C. Tan, Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics 30, 2393-2398 (2014).
76. R. Limame, A. Wouters, B. Pauwels, E. Fransen, M. Peeters, F. Lardon, O. De Wever, P. Pauwels, Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-Time technology and classic endpoint assays. PLOS ONE 7, e46536 (2012).